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In recent years, polymerase chain reaction–based genotyping 
platforms, which provide a predicted phenotype, have increased 
in both patient and high-throughput donor testing, especially 
in situations where serologic methods or reagents are limited. 
This study looks at the concordance rate between two platforms 
commercially available in the United States when used for testing 
samples from patients with sickle cell disease (SCD), a group 
particularly vulnerable to alloimmunization. DNA extracted 
from samples from 138 patients with SCD was tested by human 
erythrocyte antigen (HEA) BeadChip (Immucor, Norcross, GA) 
and by ID CORE XT (Progenika-Grifols, Barcelona, Spain). 
Predicted phenotype results were compared, and a concordance 
rate was calculated. Discrepancies were resolved by Sanger 
sequencing. All testing was done under an institutional review 
board–approved protocol. A concordance rate of 99.9 percent 
was obtained. Sanger sequencing was performed on four samples 
with discrepancies in the Rh blood group system. Three samples 
had a similar allelic variant detected by ID CORE XT. Two of the 
three discrepant samples were correctly identified as V+w, VS− 
by ID CORE XT but not by HEA BeadChip. The third sample, 
predicted to have a phenotype of V+, VS+ by sequencing, was 
called correctly by HEA BeadChip but not by ID CORE XT, which 
had predicted V+w, VS−. The fourth discrepancy was identified in a 
sample that ID CORE XT accurately identified as RHCE*ce[712G] 
and predicted a partial c phenotype. This result was confirmed 
by Sanger sequencing, whereas HEA BeadChip found no variants 
and predicted a c+ phenotype. The high concordance rate of 
the two methods, along with the known limitations of serology, 
warrant further discussion regarding the practice of serologic 
confirmation of extended phenotypes. Clinical significance 
of the identified discrepancies remains to be determined. 
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Alloimmunization is a known complication in which 
patients develop antibodies to non-self, red blood cell (RBC) 
antigens after exposure through transfusion, transplant, 
or pregnancy. Patients with sickle cell disease (SCD) are 
especially vulnerable, with up to 47 percent of transfused 
patients reported to be alloimmunized.1–8 A majority of these 
alloimmunization events occur within the Rh and Kell blood 
group systems. Providing antigen-matched blood for antigens 
in these two blood group systems has been shown to reduce 
alloimmunization rates in patients with SCD.5,9 Extended 
matching to include antigens in the Kidd, Duffy, and MNS 
blood group systems has further reduced alloimmunization 
rates.6,10 Alloimmunization mitigation is extremely important 
in decreasing delayed hemolytic transfusion reactions, which 
occur in 4–11 percent of patients with SCD and can be life 
threatening.11–13 Additionally, recent studies have shown that 
alloimmunization may contribute to increased pain episodes 
and decreased patient survival by delaying transfusion while 
searching for compatible RBC units.8,14
Although providing antigen-matched RBCs based on 
serologic phenotyping before transfusion of patients with 
SCD has decreased alloimmunization rates, it has not 
eliminated alloimmunization, primarily due to Rh variation, 
as shown by Chou et al.15 Serology is limited by its inability to 
detect variant antigens, the unavailability of antisera to rare 
or low-prevalence antigens, and its inability to provide valid 
results in recently transfused patients.
Polymerase chain reaction (PCR)-based genotyping 
platforms have been increasingly used to provide extended 
antigen-matched blood for patients requiring chronic 
transfusion16–18 (e.g., patients with SCD or warm autoimmune 
hemolytic anemia), for recently transfused patients, or for 
patients with complex serologic workups. Genotyping can 
assist in identifying antigen-negative units when commercial 
antisera are unavailable or when the assistance of rare donor 
registries is required to obtain high-prevalence antigen-
negative blood for transfusion. Several studies have compared 
molecular genotyping platforms with serologic phenotyping 
in patients and donors, with excellent concordance rates.16,19–21 
Two PCR-based molecular genotyping platforms 
commercially available in the United States for blood group 
genotyping are the human erythrocyte antigen (HEA) 
PreciseType (formerly HEA BeadChip; Immucor, Norcross, 
GA) and ID CORE XT (Progenika-Grifols, Barcelona, Spain). 
(Note: This study was performed before release of the U.S. 
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Food and Drug Administration–approved HEA PreciseType 
Molecular BeadChip reagents and used the research-use-only 
HEA BeadChip reagents. Both kit versions interrogate the 
same genetic variants and predict the same antigens.) The 
HEA BeadChip and ID CORE XT assays are very similar, 
although the differences could result in discordant findings 
and/or provide information unique to one assay. For instance, 
HEA BeadChip includes assays for antigens in the LW and 
Scianna blood group systems, whereas ID CORE XT does 
not. Similarly, ID CORE XT includes an assay for antigens in 
the Cartwright blood group system, whereas HEA BeadChip 
does not. More importantly, the assays interrogate some 
different single nucleotide variants (SNVs), especially in the 
Rh blood group system. The predicted phenotype result takes 
into account the presence or absence of variant sequences at 
polymorphic positions as well as population frequency of alleles 
when reported in the literature. These assays may differ in the 
genotype call made by the software algorithm, which may 
result in a discordant predicted phenotype for the sample. This 
study compared samples tested by both assays to determine 
the resulting concordance rate in patients with SCD. 
Materials and Methods
A total of 138 samples from patients with SCD were sent 
to LifeShare Blood Center (Shreveport, LA) for molecular 
genotyping between 2013 and 2016. DNA was extracted using 
automated QiaCube (Qiagen, Hilden, Germany) or manual 
validated procedure (Puregene; Qiagen). Qualitative and 
quantitative assessment of the DNA samples was performed 
by spectrophotometry (NanoDrop; Thermofisher, Waltham, 
MA) before their use in the molecular genotyping assay. 
Molecular genotyping was performed using HEA BeadChip 
at LifeShare Blood Center. The extracted DNA aliquots were 
stored at −20°C.
The de-identified frozen DNA samples were transported 
to the ITxM Immunohematology Reference Laboratory 
(Virginia Blood Services, Richmond, VA, now an affiliate 
of Blood Systems, Inc.) and tested using the ID CORE XT 
platform. ID CORE XT is an automated testing platform that 
analyzes 29 polymorphisms predicting 37 antigens in the Rh, 
Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Cartwright, 
and Lutheran blood group systems. 
The HEA BeadChip data were compared with the ID 
CORE XT data after all testing was completed. Discrepancies 
were defined as differences in antigens common to both 
platforms. Samples with phenotype discrepancies were sent 
to Grifols IHC (San Marcos, TX) for resolution by Sanger 
sequencing. The compiled data were then used to calculate the 
concordance rate and to evaluate the discrepancies. The study 
was performed under an institutional review board–approved 
protocol.
The possible predicted phenotype results of each of 
the antigens determined by ID CORE XT were as follows: 
positive; negative; no call (NC): if the genotyping platform 
is unable to assign a phenotype; and unknown (UN): if the 
particular combination has not been previously described as 
associated with a phenotype. If a sample generated an NC 
or UN result, the DNA quality and quantity were verified by 
spectrophotometry before including the data in the tally. 
Results
Predicted phenotype results were comparable across 
platforms for 31 antigens. Thus, for the 138 patient samples, 
there was a total of 4278 comparable calls. Three antigens were 
NC or UN by ID CORE XT and were therefore excluded from 
the concordance tally. HEA BeadChip does not interrogate an 
SNV associated with expression of the Mia antigen; therefore, 
Mia was not included in the comparison. Likewise, LW, 
Scianna, and Cartwright antigens were not included in the 
analysis for discrepancies or in our concordance calculation. 
We found four discrepant results. Thus, the concordance rate 
was 99.9 percent (100 × [4275 − 4]/4275). 
All four discrepancies were in the Rh blood group system 
(Table 1). ID CORE XT identified the RHCE*ceAR allele in 
three samples. This allele encodes a partial c, partial e, V+w, 
VS− phenotype. Two of the three samples were confirmed 
to have an RHCE*ceAR, RHCE*ce genotype by sequencing. 
The third sample was found to have an RHCE*ceVS.01, 
RHCE*ceBI genotype for a predicted V+, VS+ phenotype. 
HEA BeadChip predicted all three samples to be V+, VS+.
ID CORE XT accurately identified RHCE*ce(712G) in 
two samples. One sample was RHCE*Ce, RHCE*ce(712G), 
for which ID CORE XT predicted a partial c phenotype that 
was confirmed by Sanger sequencing. HEA BeadChip did 
not find a variant allele in this sample. The other sample was 
RHCE*ce, RHCE*ce(712G). The RHCE*ce allele encodes a 
normal c antigen. Therefore, the predicted phenotypes were 
in agreement for the two platforms (data not shown). HEA 
BeadChip predicted all three samples to be V+, VS+ because 
of interrogation of only c.733 and not c.712 by this platform.
Two samples were NC for Rh and Dombrock blood group 
systems on ID CORE XT because of insufficient DNA quality 
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and/or quantity as determined by spectrophotometry. In both 
cases, HEA BeadChip predicted common phenotypes. The 
antigens in these two blood group systems were not inves-
tigated further by sequencing and, therefore, were not tallied 
in the concordance rate. Nonetheless, these samples are in-
cluded in Tables 2 and 3 because valid phenotype predictions 
were obtained for other antigens. One other sample was UN 
for S on ID CORE XT. Sequencing detected the presence 
of Mia encoding variant c.140A on a GYPB*S background, 
whereas the ID CORE XT software only recognizes it on a 
GYPB*s background. Thus, this finding was not included as 
a discrepancy in the calculation of the concordance rate. The 
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HEA = human erythrocyte antigen; gDNA = genomic DNA.
† The ID CORE XT report includes the following description: Also possible although less likely: RHCE*ce[712G], RHCE*ce[733G]. Possible phenotype: c+ weak 
or partial, e+ weak or partial, VS+, V+.
‡The bracket in allele descriptions refer to the fact that the analysis of the gene has been limited (targeted) to certain key positions.
Table 2. Percent of samples in this study with genotypes predicted to encode an hrB–, Fy(b–), or Fy(b+) phenotype
Percent (n); N = 138
Predicted phenotype Genotype ID Core XT Genotype HEA BeadChip Found in this study Total
hrB–, V+, VS+† RHCE*ce[733G]
RHCE*ce[733G], RHCE*ce[733G, 1006T]
RHCE*cE, RHCE*ce[733G]
L245V (BB), G336C (AA)
L245V (BB), G336C (AB)





hrB–, V–, VS+ RHCE*cE, RHD*r'S−RHCE*ce[733G, 1006T] L245V (AB), G336C (AB) 1.4 (2)
Fy(b–) (GATA) FY*A, FY*B_GATA
FY*B_GATA
FYA/FYB (AB), GATA (AB)







FYB/FYB (BB), GATA (AB)
FYB/FYB (BB), GATA (AA)





Fy(b–) FY*A FYA/FYA (AA), GATA (AA) 1.4 (2) 1.4 (2)
HEA = human erythrocyte antigen.
† RHCE*ce[733G], RHCE*ce[733G, 1006T], and RHCE*cE, RHCE*ce[733G] genotypes are recently reported to predict an hrB+vw/– phenotype.  
http://www.isbtweb.org/fileadmin/user_upload/ISBT004-RHCE-15th_July_2019.pdf.22
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predicted phenotypes for all other antigens common to both 
platforms were non-discrepant.
Other phenotype information obtained by genotyping 
(without serology) is also reported. Table 2 shows the predicted 
phenotype for the Duffy blood group system based on the 
presence or absence of the GATA mutation in the promoter 
region of the gene. A GATA mutation affecting Fyb expression 
was found in 110 of the 138 samples (79.7%). 
We found a relatively large number of samples that lacked 
or had altered high-prevalence antigens not routinely detected 
by serology. In particular, 15 hrB−, 1 U−, 1 Jo(a−), and 1 Hy− 
sample were identified (Table 3).
Discussion
Blood group genotyping is particularly useful in 
chronically transfused patients with SCD or other patient 
populations with a high risk of alloimmunization. In this 
study, we compared two blood group typing assays in chroni-
cally transfused patients with SCD. Results showed a high 
concordance rate between the two genotyping platforms. 
The findings of the current study were consistent with 
those of Casas et al.,16 who demonstrated high concordance 
(99.9%) between serologic phenotyping and PCR-based 
genotyping platforms when antigens that were common 
to both methods were compared. Additional information, 
however, was obtained via genotyping that was not identified 
using serologic methods. That study found that 66 of 494 
subjects either lacked or possessed a variant high-prevalence 
antigen detected by genotyping. Additionally, 404 of 410 
patients serologically determined to be Fy(b−) were found by 
genotyping to have the GATA mutation. Finally, 23 patients 
had a partial C (serologically typed as C+) and are at risk 
for producing alloanti-C. Meyer et al.19 also found high 
concordance between serotyping and a high-throughput 
matrix-assisted laser desorption/ionization, time-of-flight 
mass spectrometry assay for Kell, Kidd, and Duffy antigens 
(the lowest concordance reported was 99.2%). They detected 
new alleles using their molecular platform. 
Our study showed that identified discrepancies between 
the two assays primarily occurred in the highly variable Rh 
blood group system. In some cases, the two assays interrogated 
different positions in the gene, and the software made 
different assumptions based on the population frequency of 
the alleles. For example, ID CORE XT interrogated position 
c.712; RHCE*ceAR includes variants c.712G and c.733G. It is 
noteworthy that these two variants can also be found in trans. 
The algorithm in the ID CORE XT software was designed to 
report RHCE*ceAR whenever c.712G and c.733G occurred in 
heterozygosity, based on the manufacturer’s experience that 
these variants were found together significantly more often 
than in trans. Thus, ID CORE XT predicted the phenotype 
based on this assumption and included a note indicating 
that an alternative genotype was possible but less likely. This 
assumption led to the reported RHCE*ceAR allele as the most 
likely result in three samples. The assumption proved true for 
two of the samples. The sample for which ID CORE XT was 
wrong had c.712G as part of RHCE*ceBI and c.733G as part 
of RHCE*ceVS.01. Therefore, ID CORE XT correctly predicted 
the phenotype in two of the three samples. HEA BeadChip 
correctly predicted the phenotype in one of the three samples 
because of its lack of interrogation of c.712. It should be noted 
that these assays are of medium resolution, and variants may 
be missed by assays of this type. 
These differences account for the discrepancies seen in 
the predicted phenotype results of the two assays. The clinical 
significance of these discrepancies is unknown. However, 
in one of the samples reported here, ID CORE XT correctly 
Table 3. Prevalence of antigens not typically analyzed by serologic 
methods in the cohort of patients with sickle cell disease (N = 138)
Blood group system Antigen Positive, n Negative, n Prevalence
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predicted a partial c expression rather than a conventional 
c+ expression. This finding theoretically could have clinical 
implications. A donor sample could be inappropriately sero-
typed as c− and expose a patient requiring c− blood to a poten-
tially immunizing partial c or result in potential increased 
clearance of the donor RBCs in a patient with preformed anti-c. 
If the patient’s sample was inappropriately serotyped as c+, 
the patient would not be recognized as requiring c− blood to 
prevent alloimmunization. 
Importantly, as reported by Casas et al.,16 genotyping 
platforms can provide additional information about the lack of 
or presence of altered high-prevalence antigens not available 
through serology alone, making these platforms of benefit 
to transfused patients. Table 3 is a modification of the table 
created by Casas et al.16 using the prevalence rates of our 
cohort. Antigen prevalence found in our current study were 
consistent with those reported by Casas et al.16 and Reid et al.23
Finally, the number of patients in our study with a 
predicted phenotype of Fy(b–) and Fy(b–) with the GATA 
mutation were similar to those reported by Casas et al.16 
Wilkinson et al.24 reported similar rates of the GATA mutation 
in patients with SCD who they genotyped. 
One important limitation of this study was the sample 
size, which affects the validity of the concordance rate. 
Additionally, these data must be interpreted with caution 
because the special cohort of patients with SCD may yield 
different concordance rates than those found when analyzing 
other populations, such as donors and patients with warm 
autoimmune hemolytic anemia who may have a less 
homologous ethnic background. Patients with SCD are largely 
of African ancestry, a population characterized by a higher 
frequency of variant RH alleles. Therefore, concordance rate 
in other populations remains to be elucidated. Nevertheless, 
a similar study using 1000 samples from random donors, 
patients, and neonates showed a high concordance rate similar 
to that seen in this population.25 Additionally, the serology 
data would have made a good complement to the resolution of 
discrepancies by DNA sequencing.
Conclusions
Genotyping provides valuable information not available 
by serologic methods, such as silencing of Fyb expression by 
the GATA mutation in the FY*B promoter and missing or 
variant high-prevalence antigens. Results from samples tested 
on both the HEA BeadChip and ID CORE XT genotyping 
platforms were found highly concordant. Discordance in the 
predicted phenotype most commonly occurs in the Rh blood 
group system because of differences in the interrogated SNVs 
and in the prediction algorithms. The clinical significance of 
the discordant results remains to be determined. 
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